I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Neuromyelitis Optica Spectrum Disorder (NMOSD)

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Apr 17 / Roche and Genentech
Infection in NMOSD: Analyzing the patterns of infection in the SAkura studies, satralizumab▼ post-marketing data, and NMOSD US PharMetrics claims data
This analysis aimed to evaluate the pattern of infection following long-term satralizumab▼ treatment in the SAkura studies, and to compare the post-marketing (PM) experience to real-world data (RWD) from a US claims database (where >99% of patients were not receiving satralizumab▼).

Sign up or login to unlock the full suite of MEDICALLY features

Apr 17 / Roche and Genentech
Long-term efficacy of satralizumab▼ in patients with AQP4-IgG+ NMOSD: Updated analysis from the open-label SAkuraMoon study
The long-term efficacy of satralizumab▼ was evaluated in patients with AQP4-IgG-seropositive NMOSD with up to 8.9 years of treatment (median exposure: ~5.9 years), in the open-label SAkuraMoon study (NCT04660539).

Sign up or login to unlock the full suite of MEDICALLY features

Apr 17 / Roche and Genentech
Burdens of Neuromyelitis Optica Spectrum Disorder: Real-World Perspectives From Caregivers
The burden of care for caregivers of individuals with neuromyelitis optica spectrum disorders (NMOSD) has not been well characterized. This study explored experiences of NMOSD caregivers and potential impacts of caregiving on their own health and well-being. Outcomes for NMOSD caregivers were compared with those in the US general population, including non-caregivers, non-NMOSD/non-multiple sclerosis (MS) caregivers and MS caregivers.

Sign up or login to unlock the full suite of MEDICALLY features

Mar 3 / Roche and Genentech
Satralizumab▼ treatment in adults with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder: a retrospective case series
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune neuroinflammatory disease. Satralizumab▼ is a humanised monoclonal recycling antibody against the interleukin 6 receptor with demonstrated safety and efficacy in patients with NMOSD in 2 randomized, placebo-controlled Phase III clinical trials (SAkuraSky [NCT02028884] and SAkuraStar [NCT02073279]). The objective of this real-world, retrospective case series was to describe the experience with satralizumab▼ in adults with AQP4-IgG+ NMOSD in clinical practice.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 7 / Roche
Brain exchange: Not all it seems? Following the clues in neuroimmunology
This session will open with a brief case of clinical demyelination and a discussion of the diffential diagnosis. The presenters will then co-lead a discussion on the underlying mehanism of disease (e.g. pathologic auto-antibodies) and the links to the diagnostic testing and interpretation. This session will primarily discuss NMOSD and MOGAD.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 7 / Roche
Watch: Not All it Seems? Following the Clues in Neuroimmunology
Watch this brain exchange, which explores MS, NMOSD, and MOGAD, with a focus on clinical demyelination, the underlying mechanisms of disease, and how they link to diagnostic testing and interpretation.
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback